Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 3Seizures 3Sturge-Weber Syndrome 2Nausea 2Vomiting 1Parasomnias 1Pain 1Neoplasms 1Marijuana Abuse 1Dysgeusia 1Drug Resistant Epilepsy 1Cognitive Dysfunction 1Chemotherapy-Induced Peripheral Neuropathy 1Cancer Pain 1Cachexia 1Breast Neoplasms 1Behavior 1Arthralgia 1Appetitive Behavior 1Anxiety Disorders 1

Interventions

Therapeutics 9Psychiatric Rehabilitation 9Music Therapy 8Cognitive Behavioral Therapy 7Mindfulness 6Surveys and Questionnaires 5Counseling 5Acupuncture Therapy 5Standard of Care 4Mindfulness-Based Stress Reduction 4Methods 4Imagery, Psychotherapy 4Early Intervention, Educational 4Autogenic Training 4Art Therapy 4Therapeutic Touch 3Psychosocial Intervention 3Psilocybin 3Mindfulness-Based Cognitive Therapy 3Massage 3Hypnosis 3Exercise 3Control Groups 3Aromatherapy 3Acceptance and Commitment Therapy 3Yoga 2Touch 2Observation 2Niacin 2Gabapentin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Anxiety Disorders × Cannabidiol × Clear all
NCT03948074 2025-09-10

CAFCARS

British Columbia Cancer Agency

Phase 2 Completed
91 enrolled

Anxiety Disorders, Nausea, Pain, Parasomnias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡